北京若生智能科技有限公司
Drug Database
BE

bevacizumab (BP 01 / Bevqolva / BP01)

✓ Approved

Aurobindo Pharma Limited · VEGFA · 单克隆抗体

什么是 bevacizumab？

bevacizumab 是一种单克隆抗体，由Aurobindo Pharma Limited研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intravenous (IV)。

药物档案

商品名BP 01, Bevqolva, BP01
公司Aurobindo Pharma Limited
药物类别单克隆抗体, 抗体
分子靶点VEGFA
给药途径Injectable (Others), Intravenous (IV)
状态Approved
来源： ClinicalTrials.gov, Aurobindo Pharma Limited

作用机制

分子靶点

bevacizumab 作用于 1 个分子靶点：

VEGFAvascular endothelial growth factor A (VPF, MVCD1)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

bevacizumab 针对 9 个适应症，涉及 2 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-small cell lung cancer stage IV✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-small cell lung cancer metastatic✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Ovarian cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Renal cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Colorectal cancer✓ Approved

注册免费账户还可查看另外 4 个适应症

免费注册查看全部适应症 →

相关研究文献

PubMedJournal of neuro-oncology2026-09-10

Diffusion histogram analysis predicts progression-free survival in contrast enhancing recurrent IDH mutant gliomas treated with bevacizumab.

Loxterkamp Elizabeth E, Luo Audrey A, Sanvito Francesco F, Le Collin T CT et al.

Pretreatment apparent diffusion coefficient (ADC) histogram analysis-specifically the lower Gaussian peak mean (ADC-L)-is a predictive biomarker of progression-free survival (PFS) and overall survival (OS) in recurrent IDH-wildtype glioblastoma receiving anti-VEGF treatment including bevacizumab. IDH-mutant gliomas differ biologically from glioblastoma, as they exhibit lower tumor cellularity, longer survival, and distinct sensitivity to a variety of therapies. Whether ADC-L retains predictive utility in IDH-mutant recurrent glioma has not been established. In this retrospective, single-center study, sixty patients with IDH-mutant recurrent glioma (41 astrocytoma, 19 oligodendroglioma) with measurable contrast enhancement and available pretreatment diffusion-weighted MRI who received bevacizumab were analyzed. Univariate and multivariate Cox regression and Kaplan-Meier analyses were performed for PFS and OS. The optimal ADC-L threshold was 1.19 μm2/ms. High ADC-L (≥1.19 μm2/ms) was associated with significantly longer PFS (median 5.46 vs. 2.76 months; p = 0.006) but not OS. In multivariate analysis, low ADC-L (HR = 2.054; p = 0.0228) and astrocytoma histology (HR = 2.295; p = 0.0158) were independent predictors of shorter PFS when accounting for number of prior recurrences. ADC-L was also significant predictor of PFS in both astrocytoma and oligodendroglioma patients, independently, after accounting for number of recurrences. Pretreatment ADC-L predicts PFS in IDH-mutant recurrent glioma receiving bevacizumab. Supporting prospective evaluation of ADC-L as a biomarker for bevacizumab patient selection in this population.

PMID 42717134
阅读全文 →
PubMedNeuro-oncology advances2026-09-10

[18F]FET PET imaging for early response assessment of bevacizumab in recurrent glioblastoma.

Chiranth Shivani S, Henriksen Otto Mølby OM, Hasselbalch Benedikte B, Grunnet Kirsten K et al.

Bevacizumab combination therapy has shown response in approximately 25% of recurrent glioblastoma (GBM) patients. This study aimed to investigate the value of O-(2-18F-fluoroethyl)-l-tyrosine positron emission tomography ([18F]FET PET) imaging and the relevance of the PET-based response assessment criteria for diffuse gliomas (PET RANO) criteria in assessing response to bevacizumab combination therapy in recurrent GBM. All recurrent GBM IDH-wildtype patients treated with bevacizumab plus irinotecan at Rigshospitalet (years 2018-2022) and evaluated with consecutive [18F]FET PET imaging at baseline and after 2 cycles of treatment were included. Metabolic tumor volumes (MTV), maximum tumor-to-background ratios (TBRmax), mean tumor-to-background ratios (TBRmean) and associated changes were determined. Cox regression and receiver operating characteristic analyses were used to identify predictors of survival beyond the median overall survival (OS). A total of 82 patients (median OS 9.3 months, 95% confidence interval: 8.3-10.4) were included. Tumors were smaller and less metabolically active at follow-up. PET RANO showed a 68% response rate and was independently associated with a longer OS (P < .001). Analysis of individual PET parameters identified 3 thresholds that independently predicted longer OS with response rates of 35%-40%: (i) more than 76% reduction in MTV, (ii) more than 21% reduction in TBRmax, and (iii) follow-up MTV under 3.5 cm3. On using [18F]FET PET for response assessment during bevacizumab treatment, the proposed response criteria improved identification of responders when compared with the PET RANO criteria. Nevertheless, further refinement and validation is needed to enhance PET-based response assessment.

PMID 42719446
阅读全文 →
PubMedAdvanced healthcare materials2026-09-10

A Spatially Controlled Glioblastoma-on-a-Chip for Dissecting Tumor-Immune-Vascular Crosstalk and Bevacizumab Resistance.

Wang Zixuan Z, Gao Jie J, Chan Junned J, Fang Yongcong Y et al.

Glioblastoma (GBM) is an aggressive brain malignancy with a median survival of only 15 months despite current therapeutic interventions. A major obstacle to effective treatment is the intricate tumor microenvironment (TME), which drives tumor progression and therapy resistance. However, existing in vitro models lack micrometer-scale spatial control over multiple cellular components and fail to preserve their dynamic interactions, limiting our understanding of tumor biology and treatment responses. Here, we present a spatially controlled GBM-on-a-chip (scGoC) platform that integrates a novel organoid positioning strategy, enabling the reconstruction of the TME within a 3D matrix at micron-level precision. This platform allows real-time monitoring of dynamic tumor-immune-vascular interactions, providing refined insights into tumor progression and drug responses. Using the scGoC, we demonstrate that endothelial cells not only promote microglial migration toward tumor organoids but also drive their polarization toward an immunosuppressive phenotype, faithfully recapitulating hallmark features of GBM progression. Importantly, the platform reveals a pro-tumorigenic adaptive response to bevacizumab monotherapy, driven by the upregulation of HIF-1 signaling and metabolic reprogramming pathways, providing mechanistic insights into GBM treatment. Collectively, the scGoC establishes a versatile and standardized tool for decoding complex cellular communications and investigating mechanisms of treatment response with broad applicability across cancer research.

PMID 42717630
阅读全文 →
PubMedStem cells international2026-09-10

Mechanisms of Mesenchymal Stem Cell-Derived Exosomes in Dry Eye Disease: From Inflammation Pathways to Therapeutic Prospects.

Yi Jiahuan J, Lu Fangfang F, Tian Yale Y, Wang Yu Y et al.

Dry eye disease (DED) is a chronic ocular surface disorder triggered by tear film imbalance, in which inflammatory disruption of immune homeostasis constitutes the core pathological mechanism. Mesenchymal stem cell-derived exosomes (MSC-Exos) offer promising anti-inflammatory therapeutic potential through immune modulation, tissue repair, and their inherently low immunogenicity. This review elucidates MSC-Exos' molecular regulation of DED inflammation, demonstrating their suppression of the TLR4/NF-κB signaling axis, the IRAK1/TRAF6/NF-κB cascade reaction, the STAT3 transcriptional regulatory network, and the NLRP3 inflammasome activation pathway, while revealing a synergistic mechanism through which MSC-Exos ameliorate the ocular surface inflammatory microenvironment by modulating the Th17/Treg immune balance via the gut-eye axis and facilitating FBXW7-mediated ubiquitination degradation pathways. Despite this therapeutic potential, clinical translation is hampered by exosomal heterogeneity, difficulties in standardization, and suboptimal delivery efficiency and long-term efficacy. Future progress will require the integration of nanotechnology and gene editing to enhance therapeutic functionality, ultimately positioning MSC-Exos as precision biologics for DED.

PMID 42719581
阅读全文 →
PubMedAAPS PharmSciTech2026-09-10

From Liquid to Gel: Multifunctional Stimuli-responsive Polymers for Targeted Oral Drug Delivery.

Mishra Manoj Kumar MK, Shukla Divaker D, Sharma Shalini S, Sharma Jyoti Nanda JN et al.

Oral drug delivery is the delivery method of choice, as it is non-invasive and patients will comply with the delivery method, but many contemporary therapeutics, such as poorly soluble, permeable, and unstable drugs, fail because of rapid gastrointestinal absorption, enzyme degradation, and non-targetability. The in-situ gelling systems are now considered paradigms that no longer exist as liquids; instead, they form a depot in the gastrointestinal tract and transform into a gel in response to physiological signals such as pH, ions, or enzymes. This review will discuss how these so-called smart polymers have developed over the years, starting as simple gel-forming systems and evolving into the multifunctional platforms that are also designed to have a pointed and sustained action. Next generation in situ gels combine bioadhesion, permeation enhancement, and active targeting ligands to overcome sequential barriers to delivery transit, permeability, stability, and cellular uptake. We critically assess the chemistry, mechanisms, formulation strategies, and therapeutic use of these systems, including gastro-retention and localized therapy, as well as oral delivery of biologics. Despite encouraging preclinical results, we touch on translational issues of scalability, manufacturing, and regulatory pathways. Multifunctional stimuli-responsive polymers, which actively traverse the gastrointestinal environment, are the future of oral drug delivery because they provide precision, bioavailability, and improved patient outcomes.

PMID 42717126
阅读全文 →
PubMedAnnals of translational medicine2026-09-10

Individualized pharmacotherapy: background and development.

Jørgensen Jan Trøst JT, Westergaard Niels N

Most drug prescriptions are still based on empiricism and not on solid biological data, which often results in considerable patient variability and, sometimes, low patient benefits. Although variability in patient response to pharmacotherapy has long been recognized, only in recent decades have new molecule analytical methods provided insight into some of the causes, which are often related to somatic or germline genetic variations. Based on this insight, different predictive biomarker tests have been developed to optimize and individualize pharmacotherapy. These biomarker tests are classified as companion diagnostic (CDx) or pharmacogenetic (PGx) tests. In both the United States and Europe, CDx and PGx information is part of the regulatory drug labeling and is included in the Prescribing Information for the individual drugs and biologics. In the United States, this type of information is found in the labeling of more than 400 regulatory-approved drugs and biological products. Despite these measures and the documented clinical utility of CDx and PGx testing, clinical implementation is lagging, especially with regard to PGx. There are various reasons for the lack of testing, such as insufficient education and awareness among healthcare professionals, inadequate access to biomarker testing, regulatory hurdles, and insufficient reimbursements. Although progress has been made in recent years, further efforts are needed to fully realize the potential of individualized pharmacotherapy by integrating the use of predictive biomarkers into routine clinical practice.

PMID 42718847
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多bevacizumab